KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Read article